Find recruiting clinical trials for melanoma in the UK — from adjuvant treatment after surgery to advanced and metastatic disease. See your treatment pathway and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
See where clinical trials fit into your treatment journey
Treatment after complete resection to reduce recurrence risk
Standard: Immunotherapy (Nivolumab or Pembrolizumab) or Targeted therapy (Dabrafenib + Trametinib for BRAF+)
Initial treatment for unresectable or metastatic disease
Standard: Nivolumab + Ipilimumab (combination) or Pembrolizumab monotherapy
After progression on immunotherapy — clinical trials especially important
Standard: Tumour-infiltrating lymphocyte (TIL) therapy, targeted therapy (BRAF+), or clinical trial
Treatment before surgery for resectable disease
Standard: Emerging — immunotherapy before surgery is an active trial area
About 40-50% of melanomas carry a BRAF V600 mutation. These patients are eligible for targeted therapy with BRAF/MEK inhibitor combinations (dabrafenib + trametinib, vemurafenib + cobimetinib).
PD-L1 is a checkpoint protein that helps predict immunotherapy response. Higher expression may indicate better response to anti-PD-1 therapy, though benefit is not limited to PD-L1 positive tumours.
About 15-20% of melanomas have NRAS mutations. These tumours tend to be more aggressive and don't respond to BRAF inhibitors. Clinical trials are especially important for this group.
Loading trials from ClinicalTrials.gov...